NNPTE
VRDN icon

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Viridian Therapeutics VRDN Stock Holding History

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-423,272
Closed -$13.2M – 56
2025
Q4 		$13.2M Hold
423,272
– – 1.17% 22
2025
Q3 		$9.13M Hold
423,272
– – 0.71% 28
2025
Q2 		$5.92M Hold
423,272
– – 0.7% 29
2025
Q1 		$5.71M Hold
423,272
– – 1.18% 25
2024
Q4 		$8.11M Sell
423,272
-209,818
-33% -$4.56M 0.98% 34
2024
Q3 		$14.4M Buy
+633,090
New +$10.4M 2% 24

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's VRDN Position: Q1 2026 in Review

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 423,272 shares — an estimated $13.2M sold.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in VRDN in Q3 2024 and held it in 6 quarters. The position peaked at $14.4M in Q3 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Nationale-Nederlanden Powszechne Towarzystwo Emerytalne reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold 423,272 Viridian Therapeutics shares in Q1 2026, an estimated $13.2M.
  • Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in Viridian Therapeutics in Q3 2024 and held it in 6 quarters.
  • Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's Viridian Therapeutics position peaked at $14.4M in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's 13F filing for Q1 2026, filed 12 May 2026.